BioSpace News Archive

Jazz Pharmaceuticals plc announced that Xyrem® (sodium oxybate) oral solution, CIII, demonstrated long-term efficacy for up to one year in reducing cataplexy and excessive daytime sleepiness (EDS) in the global Phase 2/3 EXPRESS study of pediatric patients seven to 17 years of age with narcolepsy.

Jazz Pharmaceuticals plc announced that its investigational treatment solriamfetol demonstrated long-term maintenance of efficacy and a tolerable safety profile in the open-label Phase 3 TONES 5 study of excessive sleepiness (ES) in patients with narcolepsy or obstructive sleep apnea (OSA).

The Canadian Foundation for Healthcare Improvement (CFHI) and the Government of Newfoundland and Labrador today announced that 39 long term care organizations will participate in an 18-month province-wide program designed to improve dementia care through more appropriate use of antipsychotic medications.

Sensera Inc. is adapting its technology for new applications in bioengineering.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced findings from a Phase 2 study that showed treatment with erdafitinib.

Novartis announced positive results from the third Phase III trial of Kisqali® (ribociclib) in advanced or metastatic breast cancer.

June 3, 2018 13:00 UTC Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018 – Cabozantinib improved overall survival and progression-free survival irrespective of duration of prior sorafenib treatment or age category – SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (Nasdaq: EXE

Genosco announced data from a Phase 1/2 study evaluating lazertinib (YH25448, GNS-1480) in patients with advanced Non-Small Cell Lung Cancer (NSCLC) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Seattle Genetics, Inc. and Astellas Pharma Inc. announced the presentation of updated phase 1 data of enfortumab vedotin, an investigational antibody-drug conjugate (ADC), at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

Merck announced interim results from Cohort A of KEYNOTE-427, a Phase 2 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as first-line treatment for advanced clear cell renal cell carcinoma (RCC).